PROGRAM

Thursday, May 4

Educational Session: Genomics
15:00-17:00
Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Molecular Tumor Board - Case Presentation
Lillian L. Siu, Patricio Manque, and William C. Hahn

Incorporating comprehensive tumor molecular profiling into the care of cancer patients
Patricio Manque, Universidad Mayor, Santiago, Chile

Clinical applications: Drug access and design of genotype-specific trials
Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

Opportunities for translational and discovery research: “Next-Gen” genomics
William C. Hahn, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion / Questions from audience
Lillian L. Siu, Patricio Manque, and William C. Hahn

Break
17:00-17:30

Welcome and Opening Remarks
17:30-18:00

Welcome
Margaret Foti, American Association for Cancer Research, Philadelphia, Pennsylvania
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil

Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned
18:00-19:30
Session Chair: Joao P.B. Viola, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

Title to be announced
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

State of clinical success of immune checkpoints (new preclinical data on anti-PD-1 and ant PDL-1)
Cristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
PROGRAM

Abnormal ER stress responses as new immune checkpoints in cancer
Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, New York

Opening Reception
19:45-21:30

Friday, May 5

Keynote Lecture 1
08:30-09:15
Session Chair: Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil
Title to be announced
Luisa L. Villa, Fundação Faculdade de Medicina de S Paulo, São Paulo, SP, Brazil

Break
09:15-09:45

Plenary Session 2: Tumor Heterogeneity
09:45-11:15
Session Chair: Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York
Intra-tumour genetic heterogeneity
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York
Title to be announced
Guido Lenz, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Speaker to be announced

Break
11:15-11:30

Plenary Session 3: Hematological Malignancies
11:30-1:00
Session Chair: Eliana Abdelhay, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
Epigenetic basis and therapy of hematologic malignancies
Ari M. Melnick, Weill Cornell Medical College, New York, New York
PROGRAM

Clinical networking as a tool to improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL)
Eduardo Magalhães Rego, University of São Paulo, Sao Paulo, Brazil

Novel therapeutic targets in multiple myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts

Poster Session A / Lunch
13:00-15:00

Plenary Session 4: Precision Medicine / Targeted and Combination Therapies / Drug Resistance
15:15-16:45
Title to be announced
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas

Title to be announced
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Speaker to be announced

Break
16:45-17:00

Plenary Session 5: Liquid Biopsies/Organoids/PDX
17:00-18:30
Circulating tumor DNA is a “liquid biopsy” for precision medicine: Basic concepts
Anamaria A. Camargo, Ludwig Institute for Research on Cancer, Sao Paulo, Brazil

Cancer evolution as a therapeutic target
Alberto Bardelli, University of Turin School of Medicine, Candiolo, Italy

Patient-derived xenografts and organoids to predict therapeutic response for breast cancer patients
Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah

Saturday, May 6

As of February 15, 2017
Keynote Lecture 2
08:30-09:15
Session Chair: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Title to be announced
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York

Break
09:15-09:45

Plenary Session 6: DNA Repair and PARP Inhibitors
09:45-11:15
Session Chair: Dyeison Antonow, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
Targeting DNA repair in cancer therapy
Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
Trapping PARP1 to kill cancer cells
Yves G. Pommier, National Cancer Institute-CCR, Bethesda, Maryland
Speaker to be announced

Break
11:15-11:30

Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors
11:30-13:00
Session Chair: Carlos H. Barrios, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
Title to be announced
Matthew J. Ellis, Baylor College of Medicine, Houston, Texas
Title to be announced
Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Title to be announced
Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada
Poster Session B / Lunch

As of February 15, 2017
PROGRAM

13:00-15:00

Plenary Session 8: Oncogenes and TumorSuppressors
15:15-16:45
Session Chair: Roger Chammas, University of São Paulo, Sao Paulo, Brazil

Title to be announced
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, Massachusetts

Tumor suppressor and tumor maintenance genes
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York

Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor
genome inactivation
Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil

Break
16:45-17:00

Plenary Session 9: Epigenetics
17:00-18:30

Title to be announced
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, ON, Canada

Title to be announced
Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Defining cancer specific epigenomic signature associated with glioma progression
Houtan Noushmehr, University of São Paulo, Ribeirao Preto, São Paulo, Brazil

Closing Remarks
18:30-18:45

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Carlos Gil M. Ferreira, D’or Institute for Research and Education, Rio de Janeiro, Brazil